NO20082054L - Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser - Google Patents

Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser

Info

Publication number
NO20082054L
NO20082054L NO20082054A NO20082054A NO20082054L NO 20082054 L NO20082054 L NO 20082054L NO 20082054 A NO20082054 A NO 20082054A NO 20082054 A NO20082054 A NO 20082054A NO 20082054 L NO20082054 L NO 20082054L
Authority
NO
Norway
Prior art keywords
treatment
phenylimidazo
dementia
inhibitors
new
Prior art date
Application number
NO20082054A
Other languages
English (en)
Inventor
Peter Soderman
Didier Rotticci
Tobias Rein
Helena Gyback
Erwan Arzel
Per I Arvidsson
Jeremy Burrows
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20082054L publication Critical patent/NO20082054L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse angår nye forbindelser med formel (I) som en fri base eller et farmasøytisk akseptabelt salt, solvat eller solvat av et salt derav, en fremgangsmåte for deres fremstilling og nye intermediater anvendt deri, farmasøytiske formuleringer som inneholder nevnte terapeutisk aktive forbindelser og anvendelse av nevnte aktive forbindelser ved behandling.
NO20082054A 2005-10-03 2008-04-30 Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser NO20082054L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502173 2005-10-03
PCT/SE2006/001115 WO2007040439A1 (en) 2005-10-03 2006-10-02 New compounds ii

Publications (1)

Publication Number Publication Date
NO20082054L true NO20082054L (no) 2008-06-02

Family

ID=37906402

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082054A NO20082054L (no) 2005-10-03 2008-04-30 Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser

Country Status (16)

Country Link
US (1) US20080255106A1 (no)
EP (1) EP1934217A4 (no)
JP (1) JP2009510162A (no)
KR (1) KR20080057334A (no)
CN (1) CN101321754A (no)
AR (1) AR057525A1 (no)
AU (1) AU2006297889A1 (no)
BR (1) BRPI0616663A2 (no)
CA (1) CA2624869A1 (no)
IL (1) IL189945A0 (no)
NO (1) NO20082054L (no)
SA (1) SA06270365B1 (no)
TW (1) TW200800984A (no)
UY (1) UY29823A1 (no)
WO (1) WO2007040439A1 (no)
ZA (1) ZA200802637B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
AU2008233319A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[ 4,5-B]pyridine-7-carboxamides 704
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
US9133186B2 (en) * 2010-09-10 2015-09-15 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having AMPK activating effect
WO2016008966A1 (en) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节***运动能力中的用途
US10774086B2 (en) * 2016-11-28 2020-09-15 Bristol-Myers Squibb Company GSK-3 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3711238B2 (ja) * 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドＹ受容体アンタゴニストとしての４−アミノピロ−ル（３，２−ｄ）ピリミジン
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CA2475633C (en) * 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
ATE384722T1 (de) * 2002-03-27 2008-02-15 Nycomed Gmbh Alkoxypyridinderivate
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
KR100791252B1 (ko) * 2003-01-23 2008-01-03 크리스탈지노믹스(주) 글리코겐 합성효소 키나아제 3β 활성 억제제, 이의제조방법 및 이를 유효성분으로 함유하는 약학 조성물
EA200600607A1 (ru) * 2003-10-01 2006-10-27 Алтана Фарма Аг Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
ES2309567T3 (es) * 2003-10-01 2008-12-16 Nycomed Gmbh Derivados de imidazopiridinas como inhibidores de no-sintasa inducible.
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same

Also Published As

Publication number Publication date
JP2009510162A (ja) 2009-03-12
ZA200802637B (en) 2008-12-31
AU2006297889A1 (en) 2007-04-12
CA2624869A1 (en) 2007-04-12
WO2007040439A1 (en) 2007-04-12
IL189945A0 (en) 2008-08-07
EP1934217A1 (en) 2008-06-25
KR20080057334A (ko) 2008-06-24
CN101321754A (zh) 2008-12-10
SA06270365B1 (ar) 2009-12-22
UY29823A1 (es) 2007-05-31
EP1934217A4 (en) 2010-08-04
TW200800984A (en) 2008-01-01
AR057525A1 (es) 2007-12-05
US20080255106A1 (en) 2008-10-16
BRPI0616663A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
NO20082065L (no) Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser
NO20082054L (no) Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20090328L (no) Nye forbindelser 385
NO20066055L (no) Pyridinderivater
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20071504L (no) Pyrimidinderivanter.
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
NO20071703L (no) Kinazolinderivater
NO20055219L (no) Nye forbindelser
NO20054312L (no) HIV-replikasjonsinhiberende pyrimidiner og triaziner
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20085218L (no) Nye pyridinanaloger
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
SE0402735D0 (sv) Novel compounds
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
WO2008002244A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
NO20055316D0 (no) Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20085212L (no) Nye pyridinanaloger
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application